Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Vermersch

Showing results (221-230 of 250) with videos related to

Pageof 25
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 30, 2020
BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MSMikael Cohen, Lydiane Mondot, Florence Bucciarelli, et al.
Journal of the Neurological Sciences|March 23, 2016
Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled studyLaure Peyro Saint Paul, Christian Creveuil, Olivier Heinzlef, et al.
Archives of Neurology|October 10, 2007
Acute fulminant demyelinating disease: a descriptive study of 60 patientsJérôme de Seze, Marc Debouverie, Hélène Zephir, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|September 30, 2017
Radiologically isolated syndrome in children: Clinical and radiologic outcomesNaila Makhani, Christine Lebrun, Aksel Siva, et al.
Journal of Autoimmunity|February 14, 2017
Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillanceLamiae Grimaldi-Bensouda, Michel Rossignol, Isabelle Koné-Paut, et al.
The Lancet. Neurology|September 22, 2024
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trialsXavier Montalban, Patrick Vermersch, Douglas L Arnold, et al.
Annals of Neurology|July 7, 2017
Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathyNicolas Fissolo, Béatrice Pignolet, Clara Matute-Blanch, et al.
World Journal of Urology|October 2, 2023
Development of a predictive tool for sacral nerve modulation implantation in the treatment of non-obstructive urinary retention and/or slow urinary stream: a study from the Neuro-Urology Committee of the French Association of UrologyJordan Nasri, Intisar Al Ashimi, Thibault Tricard, et al.
Plos One|March 7, 2014
Radiologically isolated syndrome: 5-year risk for an initial clinical eventDarin T Okuda, Aksel Siva, Orhun Kantarci, et al.
JAMA Network Open|April 17, 2024
An AluYa5 Insertion in the 3'UTR of COL4A1 and Cerebral Small Vessel DiseaseChaker Aloui, Lisa Neumann, Françoise Bergametti, et al.
Pageof 25

Showing results (221-230 of 250) with videos related to

Sort By:
Pageof 25
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 30, 2020
BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MSMikael Cohen, Lydiane Mondot, Florence Bucciarelli, et al.
Journal of the Neurological Sciences|March 23, 2016
Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled studyLaure Peyro Saint Paul, Christian Creveuil, Olivier Heinzlef, et al.
Archives of Neurology|October 10, 2007
Acute fulminant demyelinating disease: a descriptive study of 60 patientsJérôme de Seze, Marc Debouverie, Hélène Zephir, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|September 30, 2017
Radiologically isolated syndrome in children: Clinical and radiologic outcomesNaila Makhani, Christine Lebrun, Aksel Siva, et al.
Journal of Autoimmunity|February 14, 2017
Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillanceLamiae Grimaldi-Bensouda, Michel Rossignol, Isabelle Koné-Paut, et al.
The Lancet. Neurology|September 22, 2024
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trialsXavier Montalban, Patrick Vermersch, Douglas L Arnold, et al.
Annals of Neurology|July 7, 2017
Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathyNicolas Fissolo, Béatrice Pignolet, Clara Matute-Blanch, et al.
World Journal of Urology|October 2, 2023
Development of a predictive tool for sacral nerve modulation implantation in the treatment of non-obstructive urinary retention and/or slow urinary stream: a study from the Neuro-Urology Committee of the French Association of UrologyJordan Nasri, Intisar Al Ashimi, Thibault Tricard, et al.
Plos One|March 7, 2014
Radiologically isolated syndrome: 5-year risk for an initial clinical eventDarin T Okuda, Aksel Siva, Orhun Kantarci, et al.
JAMA Network Open|April 17, 2024
An AluYa5 Insertion in the 3'UTR of COL4A1 and Cerebral Small Vessel DiseaseChaker Aloui, Lisa Neumann, Françoise Bergametti, et al.
Pageof 25